








## ARHI CURRENT ENROLLING STUDIES

<u>Study</u>	<u>Conditions</u>	<u>Study Drug</u>	<u>Main Inclusion Criteria</u>	<u>Main Exclusion Criteria</u>
 PRESTO D7860C00006	Moderate – Severe COPD	AZD6793 Oral Tablet  Oral QD	<ul style="list-style-type: none"> <li>• <math>\geq 40</math> years of age</li> <li>• Documented history of <math>\geq 2</math> moderate or <math>\geq 1</math> severe COPD exacerbations in the 12 months prior to screening (Visit 1).</li> </ul>	<ul style="list-style-type: none"> <li>• Active pulmonary infection, pulmonary fibrosis, cystic fibrosis,</li> <li>• Significant left heart failure (NYHA III &amp; IV or left ventricular ejection fraction &lt; 40%)</li> </ul>
 THARROS D5989C00001	Mild – Moderate COPD ASCVD Hypertension Type II Diabetes Mellitus	Budesonide, Glycopyrronium, and Formoterol Fumarate Inhaler vs. Glycopyrronium and Formoterol Fumarate Inhaler Inhaler BID	<ul style="list-style-type: none"> <li>• 40 to 80 years of age</li> <li>• Current or former smokers                             <ul style="list-style-type: none"> <li>• ASCVD Event or (Hypertension, Hyperlipidemia, Type II DM, CAC &gt; 100, HF NYHA Class II or III</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Maintenance use of ICS containing inhaler within 12 months Ex; Breztri, Trelegy Ellipta</li> </ul>
 AZURE D7960C00015	Hyperlipidemia ASCVD Type II Diabetes Mellitus Hypertension	AZD0780 Oral Tablet  Oral QD	<ul style="list-style-type: none"> <li>• History of ASCVD event or Hypertension, Hyperlipidemia, T2DM, CAC &gt; 100, Prior MI, Ischemic Stroke, HF NYHA Class II or III</li> </ul>	<ul style="list-style-type: none"> <li>• Use of PCSK9 inhibitors                             <ul style="list-style-type: none"> <li>• LDL below protocol requirement</li> </ul> </li> </ul>
 EASi-PROTKT 1378-0041	ASCVD Type II Diabetes Mellitus Hypertension	Vicadrostat (BI 690517) and empagliflozin Vs. Vicadrostat (BI 690517) and Placebo Oral QD	<ul style="list-style-type: none"> <li>• Established CV disease                             <ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Type II DM</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• History of Heart Failure</li> <li>• Taking SGLT2 Inhibitors</li> </ul>

## ARHI CURRENT ENROLLING STUDIES

 novo nordisk® NN9490-8294	Obesity (BMI) $\geq$ 27.0 kg/m <sup>2</sup> & Symptomatic Osteoarthritis of Knee	NNC0487-0111 (Zenagamide) vs. Placebo Subcutaneous Injection QW	<ul style="list-style-type: none"> <li>• At least 18 years of age</li> <li>• (BMI) <math>\geq</math> 27.0 kg/m<sup>2</sup></li> <li>• Clinical diagnosis of knee osteoarthritis, X-rays demonstrating Kellgren Lawrence (KL) grades 2 to 4</li> </ul>	<ul style="list-style-type: none"> <li>• Type I or II Diabetes Mellitus</li> <li>• Treatment with GLP1, RA or GIP within 90 days of Visit 1</li> <li>• (HbA1c) <math>\geq</math> 6.5%</li> </ul>
 RENEW OP1 J2S-MC-GZMG	Current Mild, Moderate, Severe Opioid Use Disorder	Brenipatide SC Injection + Transmucosal Buprenorphine with or without Naloxone vs. Placebo SC Injection + Transmucosal Buprenorphine with or without Naloxone	<ul style="list-style-type: none"> <li>• Age 18 to 75</li> <li>• Intermittently using opioids (prescription opioids, heroin, or fentanyl)</li> <li>• Provides at least 1 opioid positive urine drug screen (other than buprenorphine)</li> </ul>	<ul style="list-style-type: none"> <li>• Type I Diabetes Mellitus</li> <li>• Uncontrolled Type II Diabetes Mellitus</li> <li>• Negative urine drug screen at screening</li> </ul>
 Move Lp(a) J2O-MC-EKBG	Established ASCVD <u>or</u> At Risk for first time event (Smoker, DMII, Older Age, Family History, Elevated coronary calcium score)	Muvalaplin vs. Placebo Oral QD	<ul style="list-style-type: none"> <li>• Age 18 +</li> <li>• Lpa <math>\geq</math> 175 nmol/L</li> </ul>	<ul style="list-style-type: none"> <li>• CV event &lt; 90 days</li> <li>• Uncontrolled Hypertension</li> <li>• Cancer within the past 5 years</li> <li>• Severe renal impairment</li> </ul>